Skip to main content
OpenTrials
Completed

NCT Number: NCT02614313

Fructose Breath-testing in Irritable Bowel Syndrome (IBS)

Background: Breath testing for food intolerances is becoming routine in patients with functional gastrointestinal disorders (FGID). Both FGID and saccharide intolerances (FODMAPs: fermentable oligo-, di-, polysaccharide and polyols, e.g. lactose, fructose, sorbitol) are common (>10% of any given population) and often respond to dietary modification. The breath tests are based on quantification of gas excretion in breath as a sign of malabsorption and symptom provocation, but are likely subject to considerable psychological bias. The role of expectation and other psychological effects on breath testing has not been reported, but is crucial for the validation of these increasingly wide-spread tests with considerable dietary and potentially deleterious consequences. Fructose has been shown to result in short term pro-inflammatory metabolic responses, but these effects have not been studied as underlying causes for intolerance symptoms in fructose intolerant patients with FGID.

Aim: To investigate the psychological component and the short-term metabolic effects of fructose breath testing in patients referred for evaluation of FGID using placebo. Additionally, to assess baseline predictors for a positive breath test result.

Methods: Fructose intolerance (defined by a positive symptom index) and malabsorption (defined by increased breath hydrogen/methane concentrations) will be determined in 30 successive male and female FGID in a single centre using breath-testing. Fructose 35g, given double-blind as well as open, a sweet placebo (cyclamate/saccharine; Assugrin®) and a neutral (still water) placebo given double-blind will be compared in a randomized, cross-over sequence and according to our standardised procedure on four separate study days. Symptoms will be recorded using standardised questionnaires and breath concentrations of H2 and CH4 will be measured during testing on the four study days. Somatisation and psychological profiles will be assessed by questionnaires. Blood samples will be obtained before and during provocation testing to assess short-term responses to fructose loading by metabolomics. Fructose, blinded and open, and placebo responses will be compared and baseline predictors for a positive breath tests assessed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gastoenterology Group Practice

Bern, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Thirty male or female FGID (Irritable Bowel Syndrome or Functional Dyspepsia according to the Rome III criteria) patients -
  • 10 healthy female and male controls
  • aged between 18 and 60 years

Exclusion criteria

  • Bowel resections, except appendicectomy or cholecystectomy
  • Evidence of organic disease
  • No medications (excluding antihypertensives, antidepressants and low-dose aspirin), including herbal, from 4 days before the first study day until after breath test
  • Coeliac's disease

Treatment and study plan

Open breath test with fructose

Procedure

Open randomised fructose 35g during breath test

Breath test with sweet placebo (Assugrin)

Procedure

Double-blind randomised breath-testing with sweet placebo (Assugrin)

Breath test with neutral placebo (still water)

Procedure

Double-blind randomised breath-testing with neutral placebo

Blinded breath test with fructose

Procedure

Double-blind randomised fructose 35g during breath test

Primary outcomes

  1. Fructose intolerance, as percentage of patients

    Time frame: 5 hours

    Defined by symptom scores

Secondary outcomes

  1. Between-group comparisons of breath test gas concentrations and symptom indices

    Time frame: 5 hours

    Breath gas concentrations and cumulative symptoms experienced during breath testing will be compared between treatment groups

  2. Correlations between breath test gas concentrations, symptom indices and metabolite

    Time frame: 5 hours

    Correlations between changes in gas levels, GI symptoms from baseline and changes in metabolites identified by metabolomic analysis in the different treatment and responder groups (i.e intolerance or no intolerance as defined by the standard breath test results). Metabotype and psychological predictors at baseline for intolerance (responder) status during breath testing will be assessed by multiple regression analysis.

Sponsors and collaborators

Lead sponsor

Brain-Gut Research Group

Other

Collaborators

  • National University of Singapore
  • New Jersey Medical School

Registry information

Official study title

Assessment of Psychological and Metabolic Responses During Fructose Intolerance Breath Tests in Patients With Functional GI Disorders: Placebo-controlled Breath Testing

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 25, 2015
Registry last updated
Dec 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.